Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.
Journal: Obesity pillars
Published: May 29, 2026
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
Journal: The New England journal of medicine
Published: September 17, 2025
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
Journal: Lancet (London, England)
Published: September 10, 2025
Improvement in body mass index category was associated with improved cardiometabolic measures and patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide.
Journal: Diabetes, obesity & metabolism
Published: March 20, 2025
Neurocognitive manifestation after treatment of pediatric severe anaphylaxis.
Journal: BMC neurology
Published: February 05, 2024
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Journal: Diabetes, obesity & metabolism
Published: October 03, 2022
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective.
Journal: Diabetes, obesity & metabolism
Published: May 19, 2022
Venolymphatic Malformation of the Labia in a 12-Year-Old Child.
Journal: The Journal of emergency medicine
Published: February 07, 2014
Pediatric rash: dermatologic manifestations of incontinentia pigmenti.
Journal: The Journal of emergency medicine
Published: June 03, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026